【Goldman Sachs】【20220803】Takeaways Follow-up ACT-AD data reaffirms view on limited drug efficacy-8页

Goldman Sachs 信息技术 2022年 PDF 1.97 MB

Alzheimer's disease Clinical Trials drug efficacy pharmaceuticals fosgonimeton